Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012:2012:273291.
doi: 10.1155/2012/273291. Epub 2012 Jul 9.

Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus

Dandan Wang  1 , Kentaro Akiyama, Huayong Zhang, Takayoshi Yamaza, Xia Li, Xuebing Feng, Hong Wang, Bingzhu Hua, Bujun Liu, Huji Xu, Wanjun Chen, Songtao Shi, Lingyun Sun
Affiliations
Randomized Controlled Trial

Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus

Dandan Wang et al. Clin Dev Immunol. 2012.

Abstract

The clinical trial of allogenic mesenchymal stem cells (MSCs) transplantation for refractory SLE patients has shown significant safety and efficacy profiles. However, the optimum frequency of the MSCs transplantation (MSCT) is unknown. This study was undertaken to observe whether double transplantations of MSCs is superior to single transplantation. Fifty-eight refractory SLE patients were enrolled in this study, in which 30 were randomly given single MSCT, and the other 28 were given double MSCT. Patients were followed up for rates of survival, disease remission, and relapse, as well as transplantation-related adverse events. SLE disease activity index (SLEDAI) and serologic features were evaluated. Our results showed that no remarkable differences between single and double allogenic MSCT were found in terms of disease remission and relapse, amelioration of disease activity, and serum indexes in an SLE clinical trial with more than one year followup. This study demonstrated that single MSCs transplantation at the dose of one million MSCs per kilogram of body weight was sufficient to induce disease remission for refractory SLE patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rate of complete remission (a) and disease relapse (b) for patients with single and double MSCs transplantations, by Kaplan-Meier survival curve analysis.
Figure 2
Figure 2
Comparisons of SLEDAI score (a), serum albumin (b), Complement 3 (C3, (c)), and anti-double-strand DNA antibody (dsDNA, (d)) for patients with single and double MSCs transplantations, by repeated measures ANOVA. Values are the mean ± SEM.
Figure 3
Figure 3
Comparisons of proteinuria (a), serum creatinine (b), platelet count (c), and hemoglobin level (d) between patients given single or double MSCs transplantations, by repeated measures of ANOVA. Values are the mean ± SEM.
See this image and copyright information in PMC

References

    1. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008;17(5):426–430. - PubMed
    1. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus - What’s hot and what’s not! Rheumatology. 2009;48(4):332–341. - PubMed
    1. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499–3506. - PubMed
    1. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology: Mechanisms of Disease. 2011;6:457–478. - PubMed
    1. Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology. 2010;10(12):1496–1500. - PubMed

Publication types